Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

ECRAID-Base: European Clinical Research Alliance on Infectious Diseases

Blue and purple image of viruses

Trial Aim

ECRAID-Base aims to establish a long-term, self-sustainable Pan-European clinical research network.

This infrastructure would advance research in developing new diagnostic, preventive, and therapeutic strategies for managing infectious diseases. It will also facilitate in delivering much faster, more efficient and cost-effective clinical research against emerging infectious diseases (EID) and antimicrobial resistance (AMR).

Purple and orange logo reads 'ECRAID Base'

Participant Information Documents

Contact details

ecraid-base@phc.ox.ac.uk 

Horizon 2020 logo in blue

Funding details

Funding: European Union’s Horizon 2020 research and innovation programme

Sponsor: University Medical Center Utrecht (UMCU), the Netherlands

Background and Study Aims

Currently, there is a lack of international collaboration, resulting in fragmentation and isolation of research efforts, inefficient use of scarce research resources, and suboptimal response to infectious diseases.

Therefore, this perpetual Observational study will help generate rigorous evidence to improve the diagnosis, prevention, and treatment of infectious diseases. The infrastructure would be equipped to respond to public health threats effectively and rapidly through the collaboration of many different European countries and industry partners.

Who can participate? 

Participants aged 60 years and over registered with their GP practice can take part in this study if they are experiencing symptoms of an Acute Respiratory Infection (ARI).

POS-ARI-PC AUDIT: Netherlands, France, Norway, Hungary, Denmark, UK, Poland, Ireland, Belgium, Greece, Spain, Armenia, Moldova, Georgia, Croatia, Sweden, Switzerland.

POS-ARI-PC CORE: TBC

What does the study involve? 

The participants will be enrolled at participating GP practices across Europe when they present with symptoms of an acute respiratory infection. A baseline assessment would be completed and a combined throat and nose swab will be taken for study purposes. During the course of the study, participants will also need to complete an online/paper diary for 14 days.

Participants may also be invited for a qualitative interview that is entirely optional. This is to better understand their overall experience of taking part and their perspectives on this study.

What are the possible risks and benefits of participating? 

No risks to participants taking part in this study.

Participants may not personally benefit from taking part but will help inform researchers and doctors in identifying best practices for the diagnosis and management of acute respiratory tract infections. Thereby they are potentially helping society as a whole, not just their country, but also Europe and possibly the world.

TRIAL TEAM

OXFORD CO-INVESTIGATORS

EXTERNAL CO-INVESTIGATORS

Dr Alike van der Velden

Related Publications

Zaeck, L.M., Lamers, M.M., Verstrepen, B.E. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med 29, 270–278 (2023). https://doi.org/10.1038/s41591-022-02090-w

Hassoun-Kheir N, van Werkhoven CH, Dunning J, Jaenisch T, van Beek J, Bielicki J, Butler CC, Francois B, Harbarth S, Hernandez Padilla AC, Horby P, Koopmans M, Lee J, Rodriguez-Baño J, Tacconelli E, Themistocleous Y, van der Velden AW, Bonten M, Goossens H, de Kraker MEA; ECRAID-Base consortium. Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases. Clin Microbiol Infect. 2022 Dec;28(12):1528-1532. doi: 10.1016/j.cmi.2022.07.024. Epub 2022 Aug 5. PMID: 35940566; PMCID: PMC9354481.

van Beek Janko, Fraaij Pieter LA, Giaquinto Carlo, Shingadia Delane, Horby Peter, Indolfi Giuseppe, Koopmans Marion, Acute hepatitis study group. Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years. Euro Surveill. 2022;27(19):pii=2200370. https://doi.org/10.2807/1560-7917.ES.2022.27.19.2200370